# Check omega 3 claims before buying

Published by Pawel Jozefiak. [About this project](https://adhd100.jock.pl/about/), [How we check sources](https://adhd100.jock.pl/methodology/)

- Canonical: https://adhd100.jock.pl/omega-three-expectations/
- Language: en
- First published: 2026-09-29
- Evidence checked: 2026-09-29, using AI-assisted source verification
- Clinical review: Not clinically reviewed
- Number 99 of 100 in the list: https://adhd100.jock.pl/#omega-three-expectations

Before paying for a supplement for your child's ADHD, talk through the evidence and the safety.

**The number:** Low certainty: omega 3 barely differs from placebo on symptoms at about 26 weeks (SMD 0.049) ([Gosling et al., EBI-ADHD team (BMJ 2025 supplement), 2025](https://corentinjgosling.github.io/EBI-ADHD-UR-2025/))

## The evidence

- How sure: Certainty of evidence: Low certainty. Measured in people with ADHD.
- See this comparison on the evidence map: https://adhd100.jock.pl/evidence/#r-polyunsaturated-fatty-acids-youth-core-adhd-symptoms-parent-rated-medium
- Evidence grade: B. Grade B: trials in ADHD with low certainty, or strong general health evidence with a sourced reason it matters more with ADHD.
- Basis: EBI-ADHD re-estimation: 15 trials, 963 young people, parent-rated core symptoms at medium-term follow-up.
- Outcome: parent-rated core ADHD symptom difference at about 26 weeks
- Comparison: polyunsaturated fatty acids vs placebo
- Benefit: 32/100. The benefit score is an editorial prioritization for the general list, weighted by certainty. It is not a prediction of what will happen for you.

## Why it matters

EBI-ADHD found an almost zero estimated benefit from polyunsaturated fatty acids on parent-rated symptoms at about 26 weeks: SMD 0.049, with a 95% confidence interval from -0.101 to 0.198. Certainty was low, and the interval includes no benefit. The Cochrane review rated it high certainty that these supplements had no effect on parent-rated total symptoms in the medium term, SMD -0.08. So this evidence does not support promising that omega 3 supplements will improve your child's ADHD.

## How to do it

1. Ask which ADHD outcome the supplement claim rests on, and how certain the result is.
2. Bring any supplements already used to a pharmacist or clinician review.
3. Talk about nutrition separately from promises to treat ADHD.

## Talk to a clinician first

Discuss supplements with a clinician or pharmacist, especially alongside medicines. This is an evidence review, not a recommendation to self-treat.

## Putting it into practice

### Start now

- 1 minute: Write down exactly what improvement you'd expect before paying for an ADHD supplement.
- 5 minutes: List the supplements and medicines you want a pharmacist to review.
- 15 minutes: Read the Cochrane summary and prepare questions about likely benefit, cost and safety.

### What it looks like

- Ask a pharmacist to review a supplement already in your child's cupboard.
- Compare an advert's promise with the review's finding that a meaningful symptom benefit is not established.

### Common mistakes

- A tiny average estimate is no guarantee of improvement. Check the uncertainty as well as the headline.
- Supplement safety depends on the whole medicine list, so include non-prescription products in a review.

### Trusted how-to guides

- [Medication Safety and Your Health](https://www.cdc.gov/medication-safety/about/index.html), CDC

## Sources

- [Supplementary materials for EBI-ADHD](https://corentinjgosling.github.io/EBI-ADHD-UR-2025/), Gosling et al., EBI-ADHD team (BMJ 2025 supplement), 2025 (Tier 1 guideline)
- [Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making](https://pmc.ncbi.nlm.nih.gov/articles/PMC12651917/), BMJ, 2025 (Tier 1 guideline)
- [Polyunsaturated fatty acids (PUFA) supplements for attention deficit hyperactivity disorder (ADHD) in children and adolescents](https://www.cochrane.org/evidence/CD007986_polyunsaturated-fatty-acids-pufa-supplements-attention-deficit-hyperactivity-disorder-adhd-children), Cochrane, 2023 (Tier 1 guideline)
- [Medication Safety and Your Health](https://www.cdc.gov/medication-safety/about/index.html), CDC, 2024 (Tier 1 guideline)

---

General information about ADHD, not a diagnosis or an individual treatment plan. Tailoring changes the order of suggestions; it does not assess you. Medication decisions belong with you and a qualified clinician.

Report an error: meet@jock.pl

Reuse: CC BY 4.0, https://creativecommons.org/licenses/by/4.0/